FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284687931> ?p ?o ?g. }

• W4284687931 endingPage "5003" @default.
• W4284687931 startingPage "4995" @default.
• W4284687931 abstract "Although optimal treatment in early triple-negative breast cancer (TNBC) remains unclear, de-escalated chemotherapy appears to be an option in selected patients within this aggressive subtype. Previous studies have identified several pro-immune factors as prognostic markers in TNBC, but their predictive impact regarding different chemotherapy strategies is still controversial.ADAPT-TN is a randomized neoadjuvant multicenter phase II trial in early patients with TNBC (n = 336) who were randomized to 12 weeks of nab-paclitaxel 125 mg/m2 + gemcitabine or carboplatin d 1,8 q3w. Omission of further (neo-) adjuvant chemotherapy was allowed only in patients with pathological complete response [pCR, primary endpoint (ypT0/is, ypN0)]. Secondary invasive/distant disease-free and overall survival (i/dDFS, OS) and translational research objectives included quantification of a predictive impact of markers regarding selection for chemotherapy de-escalation, measured by gene expression of 119 genes (including PAM50 subtype) by nCounter platform and stromal tumor-infiltrating lymphocytes (sTIL).After 60 months of median follow-up, 12-week-pCR was favorably associated (HR, 0.24; P = 0.001) with 5y-iDFS of 90.6% versus 62.8%. No survival advantage of carboplatin use was observed, despite a higher pCR rate [HR, 1.04; 95% confidence interval (CI), 0.68-1.59]. Additional anthracycline-containing chemotherapy was not associated with a significant iDFS advantage in pCR patients (HR, 1.29; 95% CI, 0.41-4.02). Beyond pCR rate, nodal status and high sTILs were independently associated with better iDFS, dDFS, and OS by multivariable analysis.Short de-escalated neoadjuvant taxane/platinum-based combination therapy appears to be a promising strategy in early TNBC for using pCR rate as an early decision point for further therapy (de-) escalation together with node-negative status and high sTILs. See related commentary by Sharma, p. 4840." @default.
• W4284687931 created "2022-07-08" @default.
• W4284687931 creator A5011423603 @default.
• W4284687931 creator A5012681752 @default.
• W4284687931 creator A5013148496 @default.
• W4284687931 creator A5014363979 @default.
• W4284687931 creator A5016623639 @default.
• W4284687931 creator A5019569585 @default.
• W4284687931 creator A5020142852 @default.
• W4284687931 creator A5022444628 @default.
• W4284687931 creator A5026211073 @default.
• W4284687931 creator A5027231412 @default.
• W4284687931 creator A5031666050 @default.
• W4284687931 creator A5035281192 @default.
• W4284687931 creator A5036502346 @default.
• W4284687931 creator A5040331693 @default.
• W4284687931 creator A5044243143 @default.
• W4284687931 creator A5044665296 @default.
• W4284687931 creator A5053393177 @default.
• W4284687931 creator A5053751196 @default.
• W4284687931 creator A5054650117 @default.
• W4284687931 creator A5081829270 @default.
• W4284687931 creator A5087019685 @default.
• W4284687931 creator A5087224341 @default.
• W4284687931 creator A5088032345 @default.
• W4284687931 creator A5089513581 @default.
• W4284687931 creator A5090984572 @default.
• W4284687931 date "2022-07-07" @default.
• W4284687931 modified "2023-10-10" @default.
• W4284687931 title "De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial" @default.
• W4284687931 cites W1481244595 @default.
• W4284687931 cites W1484870202 @default.
• W4284687931 cites W1978158433 @default.
• W4284687931 cites W2006070721 @default.
• W4284687931 cites W2064087555 @default.
• W4284687931 cites W2075894019 @default.
• W4284687931 cites W2096864872 @default.
• W4284687931 cites W2112648444 @default.
• W4284687931 cites W2118605519 @default.
• W4284687931 cites W2120431466 @default.
• W4284687931 cites W2125885282 @default.
• W4284687931 cites W2143459396 @default.
• W4284687931 cites W2147660572 @default.
• W4284687931 cites W2264815585 @default.
• W4284687931 cites W2606920283 @default.
• W4284687931 cites W2618058692 @default.
• W4284687931 cites W2771978163 @default.
• W4284687931 cites W2772853465 @default.
• W4284687931 cites W2784030537 @default.
• W4284687931 cites W2788106879 @default.
• W4284687931 cites W2794018125 @default.
• W4284687931 cites W2805282784 @default.
• W4284687931 cites W2886991068 @default.
• W4284687931 cites W2889499644 @default.
• W4284687931 cites W2890992738 @default.
• W4284687931 cites W2895846919 @default.
• W4284687931 cites W2897422388 @default.
• W4284687931 cites W2907566829 @default.
• W4284687931 cites W2909799373 @default.
• W4284687931 cites W2911718257 @default.
• W4284687931 cites W2915774478 @default.
• W4284687931 cites W2919605631 @default.
• W4284687931 cites W2942507864 @default.
• W4284687931 cites W2944588181 @default.
• W4284687931 cites W2945384827 @default.
• W4284687931 cites W2946864408 @default.
• W4284687931 cites W2948908486 @default.
• W4284687931 cites W2979547848 @default.
• W4284687931 cites W3006134372 @default.
• W4284687931 cites W3006930853 @default.
• W4284687931 cites W3010020169 @default.
• W4284687931 cites W3048815387 @default.
• W4284687931 cites W3087393791 @default.
• W4284687931 cites W3088047261 @default.
• W4284687931 cites W3098994343 @default.
• W4284687931 cites W3168654539 @default.
• W4284687931 cites W4205664642 @default.
• W4284687931 cites W4220842908 @default.
• W4284687931 cites W4229079181 @default.
• W4284687931 cites W4280503811 @default.
• W4284687931 doi "https://doi.org/10.1158/1078-0432.ccr-22-0482" @default.
• W4284687931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35797219" @default.
• W4284687931 hasPublicationYear "2022" @default.
• W4284687931 type Work @default.
• W4284687931 citedByCount "4" @default.
• W4284687931 countsByYear W42846879312022 @default.
• W4284687931 countsByYear W42846879312023 @default.
• W4284687931 crossrefType "journal-article" @default.
• W4284687931 hasAuthorship W4284687931A5011423603 @default.
• W4284687931 hasAuthorship W4284687931A5012681752 @default.
• W4284687931 hasAuthorship W4284687931A5013148496 @default.
• W4284687931 hasAuthorship W4284687931A5014363979 @default.
• W4284687931 hasAuthorship W4284687931A5016623639 @default.
• W4284687931 hasAuthorship W4284687931A5019569585 @default.
• W4284687931 hasAuthorship W4284687931A5020142852 @default.
• W4284687931 hasAuthorship W4284687931A5022444628 @default.
• W4284687931 hasAuthorship W4284687931A5026211073 @default.
• W4284687931 hasAuthorship W4284687931A5027231412 @default.

• next